Key melanoma highlights from ASCO 2024, including RELATIVITY-048 and NADINA trials

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the significant highlights from ASCO 2024, particularly focusing on melanoma. Dr Hamid highlights data from the RELATIVITY-048 trial (NCT03470922), which evaluated the combination of ipilimumab, nivolumab, and relatlimab, showing significant progression-free survival (PFS) benefits. He notes the trial's potential in expanding to other solid tumors, given the expression of LAG-3 in various cancers. Dr Hamid also emphasizes the Phase III NADINA trial (NCT04949113), which compared neoadjuvant and adjuvant therapies, demonstrating superior event-free survival with the neoadjuvant approach. This approach may reduce drug usage, costs, and immune toxicity. Additionally, he mentions updates on a vaccine in melanoma and promising data for uveal melanoma treatments. Overall, these findings are pivotal not only for melanoma but also for shaping the future of solid tumor therapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.